Clinical Trial

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-03; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT07285291
Lead Sponsor Taisho Pharmaceutical Co., Ltd.
Conditions Hyperphosphatemia Patients on Hemodialysis
Enrollment 100 participants
Start Date 2026-01-09
Primary Completion 2026-12-22 (estimated)
Study Completion 2026-12-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-17